Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871297 · ClinicalTrials.gov registry record · Phase 3
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 662
- Enrollment target
NCT02871297 is a Phase 3 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 662 participants.
The verdict
NCT02871297, a Phase 3 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 662 participants
- Enrollment target
Study Summary
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
Interventions
- DRUG Vortioxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 662 participants |
| Start Date | 2016-08-17 |
| Est. Completion | 2022-04-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02871297
The ClinicalTrials.gov registry entry for NCT02871297 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 662 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vortioxetine is the first listed.
NCT02871297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02871297 about?
NCT02871297 is a clinical study titled "Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age". Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
What is the current status of trial NCT02871297?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 662 participants. The study started on 2016-08-17. Estimated completion is 2022-04-19.
What interventions are being tested in trial NCT02871297?
The interventions under investigation include: Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT02871297?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.